Skip to Content

GenoMed announces drug therapy to avoid dialysis in acute kidney failure

ST. LOUIS, MO., August 13, 2002 -- GenoMed, a St. Louis-based medical genomics biotechnology company, announced a new drug treatment that avoids dialysis in the setting of acute kidney failure.

Based on pilot data from a study conducted by Dr. David Moskowitz, GenoMed's Chairman and Chief Medical Officer, the drug regimen avoided the need for dialysis in over 80% of adults in the hospital with acute kidney failure. This drug regimen has also been used with similar success for neonates with acute kidney failure in the Neonatal Intensive Care Unit.

The same treatment should be useful in avoiding non-function of transplanted kidneys after harvesting from donors and immediately after placement into recipients.

Dr. Moskowitz gave the patients a loading dose and an infusion of an already existing medication, aminophylline. This specific treatment has not been used before, and is based on the physiology of why the kidney shuts down in acute kidney failure. On August 8, 2001, GenoMed filed its first application for world-wide patent protection involving aminophylline in acute kidney failure.

"Despite the introduction of kidney dialysis within the past 50 years," said Dr, Moskowitz, "acute kidney failure is still associated with a 50% mortality rate. It is a devastatingly expensive problem for all concerned. Avoiding dialysis may be the first step towards reducing the costs and mortality of acute kidney failure.

"This treatment should also be especially useful in settings without ready access to kidney dialysis machines, such as third-world hospitals or disaster sites such as earthquakes."

Source: GenoMed

Posted: August 2002